Teva Pharmaceutical Indu... Aktie - TEV

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

20,70

Gebot

20,60

Fragen

20,70

Volumen

16.027

20,40 Tagesbereich 21,00

0,00 52-Wochen-Bereich 0,00

Marktkapitalisierung

23,454B

Handelsende

20,80

Handelsbeginn

20,80

Letzte Trade

250

20.5

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

Ausgegebene Aktien

1.133.050.214

Dividendenrendite

Kurs-Gewinn-Verhältnis

-37,49

Gewinn pro Aktie (EPS)

-0,49

Erlöse

15,85B

Nettogewinn

-559M

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Preparations

Website

www.tevapharm.com

Hauptsitz

Tel Aviv, Center, Isr

Gegründet

1901

Teva Pharmaceutical Industries Ltd is listed in the Pharmaceutical Preparations sector of the Tradegate (DE) with ticker TEV. The last closing price for Teva Pharmaceutical Indu... was 20,80 €. Over the last year, Teva Pharmaceutical Indu... shares have traded in a share price range of 0,00 € to 0,00 €.

Teva Pharmaceutical Indu... currently has 1.133.050.214 shares in issue. The market capitalisation of Teva Pharmaceutical Indu... is 23,57 € billion. Teva Pharmaceutical Indu... has a price to earnings ratio (PE ratio) of -37.49.

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference TEL AVIV, Israel, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced...

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025 TEL AVIV, Israel, Dec. 20, 2024 (GLOBE...

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease Teva hosting investor call today at 8:00...

Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients

Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients Teva to provide two generic inhaler products to Direct Relief for its network of...

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan Teva entered into an agreement with JKI Co., Ltd. (“JKI”) established by the fund managed and operated by private...

Teva präsentiert positive Wirksamkeits- und Sicherheitsdaten von AJOVY® (Fremanezumab) zur Vorbeugung episodischer Migräne bei Kindern und Jugendlichen aus der Phase-III-Studie SPACE

Teva präsentiert positive Wirksamkeits- und Sicherheitsdaten von AJOVY® (Fremanezumab) zur Vorbeugung episodischer Migräne bei Kindern und Jugendlichen aus der Phase-III-Studie SPACE AJOVY®...

Teva présente des données positives sur l’efficacité et la sécurité d’emploi d’AJOVY® (frémanézumab) pour la prévention de la migraine épisodique chez les enfants et les adolescents dans le cadre de l’essai clinique de phase III SPACE

Teva présente des données positives sur l’efficacité et la sécurité d’emploi d’AJOVY® (frémanézumab) pour la prévention de la migraine épisodique chez les enfants et les adolescents dans le cadre...

Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial

Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial AJOVY® (fremanezumab...

Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference

Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference TEL AVIV, Israel, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced...

Teva to Present at the Jefferies London Healthcare Conference

Teva to Present at the Jefferies London Healthcare Conference TEL AVIV, Israel, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

TEV - Frequently Asked Questions (FAQ)

What is the current Teva Pharmaceutical Indu... share price?

The current share price of Teva Pharmaceutical Indu... is 20,70 €

How many Teva Pharmaceutical Indu... shares are in issue?

Teva Pharmaceutical Indu... has 1.133.050.214 shares in issue

What is the market cap of Teva Pharmaceutical Indu...?

The market capitalisation of Teva Pharmaceutical Indu... is EUR 23,57B

What is the 1 year trading range for Teva Pharmaceutical Indu... share price?

Teva Pharmaceutical Indu... has traded in the range of 0,00 € to 0,00 € during the past year

What is the PE ratio of Teva Pharmaceutical Indu...?

The price to earnings ratio of Teva Pharmaceutical Indu... is -37,49

What is the cash to sales ratio of Teva Pharmaceutical Indu...?

The cash to sales ratio of Teva Pharmaceutical Indu... is 1,32

What is the reporting currency for Teva Pharmaceutical Indu...?

Teva Pharmaceutical Indu... reports financial results in USD

What is the latest annual turnover for Teva Pharmaceutical Indu...?

The latest annual turnover of Teva Pharmaceutical Indu... is USD 15,85B

What is the latest annual profit for Teva Pharmaceutical Indu...?

The latest annual profit of Teva Pharmaceutical Indu... is USD -559M

What is the registered address of Teva Pharmaceutical Indu...?

The registered address for Teva Pharmaceutical Indu... is 124 DVORA HANEVI’A ST, TEL AVIV, CENTER, 6944020

What is the Teva Pharmaceutical Indu... website address?

The website address for Teva Pharmaceutical Indu... is www.tevapharm.com

Which industry sector does Teva Pharmaceutical Indu... operate in?

Teva Pharmaceutical Indu... operates in the PHARMACEUTICAL PREPARATIONS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
0S6Cerence Inc	18,972 € (145,34%)	89,94k
CY9DMicrobot Medical Inc	2,11 € (89,07%)	24,21k
RV0Torrent Gold Inc	0,138 € (73,58%)	1,23k
7CCCheckCap Ltd	1,76 € (55,75%)	6,55k
34Q0Quantum eMotion Inc	0,985 € (53,91%)	1,62M
7DBDiamondback Energy Inc	9,7176 € (-94,02%)	800
FASFastenal Co	9,7358 € (-85,95%)	2,13k
1UR1Bee Vectoring Technologies International Inc	0,003 € (-45,45%)	300,18k
B4T0CuFe Ltd	0,0045 € (-25,00%)	1
H5EHelma Eigenheimbau Ag	0,0766 € (-23,40%)	751
PF8European Lithium Limited	0,0264 € (8,20%)	5,76M
3CPXiaomi Corporation	4,597 € (7,34%)	3,95M
D7GNel ASA	0,247 € (2,66%)	2,33M
J9AVERSES AI Inc	1,352 € (0,00%)	1,67M
34Q0Quantum eMotion Inc	0,985 € (53,91%)	1,62M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Teva Pharmaceutical Industries Ltd (TEV)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Teva Pharmaceutical Industries Ltd

TEV Neueste Nachrichten

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease

Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan

Teva präsentiert positive Wirksamkeits- und Sicherheitsdaten von AJOVY® (Fremanezumab) zur Vorbeugung episodischer Migräne bei Kindern und Jugendlichen aus der Phase-III-Studie SPACE

Teva présente des données positives sur l’efficacité et la sécurité d’emploi d’AJOVY® (frémanézumab) pour la prévention de la migraine épisodique chez les enfants et les adolescents dans le cadre de l’essai clinique de phase III SPACE

Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial

Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference

Teva to Present at the Jefferies London Healthcare Conference

TEV - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Teva Pharmaceutical Industries Ltd (TEV) Börsenkurse

Teva Pharmaceutical Industries Ltd (TEV)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Teva Pharmaceutical Industries Ltd

TEV Neueste Nachrichten

TEV - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE